About Iktos
Iktos is a Healthcare company based in Paris (France) founded in 2016 by Nicolas Do Huu, Quentin Perron, and Yann Gaston-Mathe. Artificial intelligence is applied to de novo drug design processes. Iktos has raised $16.34 million across 1 funding round from investors including Debiopharm, M-Ventures and Omnes Capital. Iktos has completed 1 acquisition, including Synsight. Its chief executive, as recorded, is Yann Gaston-Mathe. Its website iktos.ai draws about 10 thousand monthly visits. Iktos offers products and services including Makya, Spaya, and Iktos Robotics. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery.
Company details
Iktos was founded in 2016 and is headquartered in Paris, France. Operations focus on the pharmaceutical sector, where artificial intelligence is employed for ligand-based de novo drug design. Emphasis is placed on multiparametric optimization to generate druggable and synthesizable molecules that meet specified criteria. The technology relies on deep learning algorithms to support these design activities.
- Total Equity Funding$16.34M (USD)
in 1 rounds
- Latest Funding Round$16.34M (USD), Series A
Mar 2023
- InvestorsDebiopharm
& 2 more
- Investments & Acquisitions
Products & Services of Iktos
Iktos offers a comprehensive portfolio of products and services, including Makya, Spaya, and Iktos Robotics.
AI tool for de novo drug design and molecular optimization.
AI for identifying feasible synthetic routes in drug development.
Robotics for automated synthesis, purification, and testing processes.
Funding Insights of Iktos
Iktos has successfully raised a total of $16.34M through 1 strategic funding round. The most recent funding activity was a Series A round of $16.34 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.34M
- Total Rounds 1
- Last Round Series A — $16.34M
- First Round $16.34M
(Mar 2023)
- Investors Count 3
All 1 funding rounds of Iktos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2023 | $16.34M | Series A | – | M Ventures, Debiopharm |
3 investors in total: 3 institutional.
Investors in Iktos
Iktos has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Debiopharm, M-Ventures and Omnes Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in multiple sectors | m-ventures.com | Amsterdam, Netherlands | ||
Private equity firm focused on energy transition and sustainable investments across Europe. | omnescapital.com | |||
Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs | 1979 | debiopharm.com | Lausanne, Switzerland |
Investor details for Iktos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Iktos
30 people are tracked at Iktos (14 in leadership, 16 in team).
| Name | Role | Group |
|---|---|---|
Nicolas Do Huu | Co-Founder & CTO | Leadership |
Quentin Perron | Co-Founder & CSO | Leadership |
Yann Gaston-Mathe | Co-Founder & CEO | Leadership |
Nicolas Do Huu, PhD | Founder, Chief Technology Officer | Leadership |
Nicolas Martin, PharmD PhD | Director, Head Of Business Development EU | Leadership |
Franck Le Vaillant | Senior Scientist - Deputy Lab Head | Leadership |
Marion Laguette | Director - Strategic Planning, Corporate Development and Operations | Leadership |
Philip Laut | Vice President, Head Of US Operations, Sales & Business Development | Leadership |
Hamza TAJMOUATI | Head of AI & Data | Leadership |
Eleonora Echegaray | Marketing & Communications Director | Leadership |
Fabien Guillemot | CFO | Leadership |
Cyril Bauvais | Director, Head Of Bio-imaging Lab | Leadership |
El Gasser Abderraouf | Head of Platform Development | Leadership |
Alexis Denis | SVP, Head Drug Discovery | Leadership |
Jean-Baptiste Chéron | Research Software Engineer | Team |
Pierre Grenut | Junior Business Development Manager | Team |
Brice Hoffmann | Principal Scientist, Group Leader, Computational Chemistry | Team |
MASSINA ABDERRAHMANE | Senior Data Scientist | Team |
Clarisse Descamps | Senior Data Scientist | Team |
Florian Kasper | Software Engineer | Team |
10 more people are available in the full profile.
Complete people profiles for Iktos
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Iktos
Iktos has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Synsight.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Services in molecular modeling, bioinformatics, and structural biology are provided. | synsight.net | Orsay, France | 2013 | Jul 2024 | •••• |
Complete acquisition details for Iktos
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Iktos
3 dated milestones of Iktos across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Iktos is founded.
- Funding First funding round of $16.3M.
- Acquisition Acquires Synsight.
Web traffic of Iktos
The website of Iktos (iktos.ai) receives about 10.3K visits a month.
- Monthly visits10.3K
▲ 56% vs previous month
Websites whose visitors overlap most with Iktos. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aqemia.com | 32% | 5.3K | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Iktos
Complete news archive for Iktos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Iktos
Iktos was founded in 2016 and raised its 1st funding round 7 years after it was founded.
Iktos is headquartered in Paris, France.
Yann Gaston-Mathe is the CEO of Iktos, as recorded in our data. They have also founded this company.
Iktos is a funded company, having raised a total of $16.34M across 1 funding round to date. The company's 1st funding round was a Series A of $16.34M, raised on Mar 2023.
Iktos was founded in 2016 and is headquartered in Paris, France. Operations focus on the pharmaceutical sector, where artificial intelligence is employed for ligand-based de novo drug design. Emphasis is placed on multiparametric optimization to generate druggable and synthesizable molecules that meet specified criteria. The technology relies on deep learning algorithms to support these design activities.
Iktos offers Makya, Spaya, and Iktos Robotics.
Iktos has made 1 acquisition, including Synsight.
Iktos has 3 investors. Key investors include Debiopharm, M-Ventures, and Omnes Capital.